

Drugs



Utomilumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name	Utomilumab		
Accession Number	DB15113		
Type	Biotech		
Groups	Investigational		
Description	Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).		
Synonyms	PF-05082566		
Categories	Amino Acids, Peptides, and Proteins	Globulins	Immunoproteins
	Antibodies	Immunoglobulin Isotypes	Proteins
	Blood Proteins	Immunoglobulins	Serum Globulins
UNII	6YY8O697VE		
CAS number	1417318-27-4		

PHARMACOLOGY

Indication	Not Available
Pharmacodynamics	Not Available
Mechanism of action	Not Available
Absorption	Not Available
Volume of distribution	Not Available
Protein binding	Not Available
Metabolism	Not Available
Route of elimination	Not Available
Half life	Not Available

Clearance Not Available

Drugs



Affected organisms Not Available



Pathways Not Available

Pharmacogenomic Effects/ADRs [i](#) Not Available

INTERACTIONS

Drug Interactions



ALL DRUGS

[APPROVED](#)

[VET APPROVED](#)

[NUTRACEUTICAL](#)

[ILLICIT](#)

[WITHDRAWN](#)

[INVESTIGATIONAL](#)

[EXPERIMENTAL](#)

Show entries

DRUG	INTERACTION
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Utomilumab.
Abituzumab	The risk or severity of adverse effects can be increased when Abituzumab is combined with Utomilumab.
Abrilumab	The risk or severity of adverse effects can be increased when Abrilumab is combined with Utomilumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Utomilumab.
Adecatumumab	The risk or severity of adverse effects can be increased when Adecatumumab is combined with Utomilumab.
Aducanumab	The risk or severity of adverse effects can be increased when Aducanumab is combined with Utomilumab.
Afelimomab	The risk or severity of adverse effects can be increased when Afelimomab is combined with Utomilumab.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Utomilumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Utomilumab.

ADDITIONAL DATA AVAILABLE

Showing 1 to 10 of 329 entries

[1](#)
[2](#)
[3](#)
[4](#)
[5](#)
[...](#)
[33](#)

Food Interactions Not Available

REFERENCES

General References Not Available

External Links [Wikipedia](#)

[CD137](#)

CLINICAL TRIALS

Clinical Trials

Show entries

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1	Completed	Treatment	Advanced Solid Tumors	1

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
			Lymphoma (FL) / Lung Cancer Non-Small Cell Cancer (NSCLC) /	-
<div style="display: flex; justify-content: flex-end; align-items: center;"> <div style="border: 1px solid #ccc; border-radius: 15px; padding: 2px 10px; margin-right: 10px;">Drugs</div> <div style="border: 1px solid #ccc; border-radius: 15px; padding: 2px 10px; margin-right: 10px;">Q</div> </div>				
1	Not Yet Recruiting	Treatment	Follicular Lymphoma (FL)	1
1	Recruiting	Treatment	CCND1 Positive / CD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Mantle Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	1
1	Recruiting	Treatment	COL6A3 Positive / HLA-A*0201 Positive Cells Present / Platinum Resistant Ovarian Cancer / PRAME Positive / Recurrent Ovarian Carcinoma	1
1	Recruiting	Treatment	Colorectal Cancers / Malignant Neoplasms of Digestive Organs / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8	1
1	Recruiting	Treatment	HER2 Positive Breast Carcinoma / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer	1
1	Terminated	Treatment	Advanced/Metastatic Solid Tumors	1
1, 2	Recruiting	Treatment	Advanced Malignant Solid Neoplasm / Castration-Resistant Prostate Carcinoma / Malignant Neoplasm of Breast / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Malignant Solid Neoplasm / Metastatic Hormone Refractory Prostate Cancer / Metastatic Malignant Solid Neoplasm / Neoplasms of Uncertain or Unknown Behavior / Neoplasms, Malignant / Prostate Carcinoma Metastatic in the Bone / Refractory Malignant Solid Neoplasm / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v8	1
1, 2	Recruiting	Treatment	Refractory Large B-cell Lymphoma	1

Showing 1 to 10 of 15 entries

⏪ 1 2 ⏩

PHARMACOECONOMICS

Manufacturers Not Available

Packagers Not Available

Dosage forms Not Available

Prices Not Available

Patents Not Available

PROPERTIES

State Not Available

Experimental Properties Not Available

TAXONOMY

Drugs

**Classification** Not classified

Drug created on May 20, 2019 08:50 / Updated on May 21, 2019 12:35

About[About DrugBank](#)[DrugBank Blog](#)[Wishart Research Group](#)[Careers](#)[Terms of Use](#)[Privacy Policy](#)**Support**[FAQ](#)[Help Center](#)[Email Support](#)**Commercial Products**[API Pricing](#)[API Docs](#)[Data Licenses](#)[Contact Us](#)

This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions**, and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**

